Redeye updates its view on Acarix following its Q2 2024 report.
While the commercialization of Crunchfish’s solution for offline payments has shown a longer sales c...
Redeye is encouraged by the recent commercial progress, particularly in the Chinese market.
Redeye provides an update following CLS’ Q2 report that fairly aligned with our expectations and did...
Redeye makes upward estimate revisions on the back of I-Tech’s solid Q2 figures.
Redeye sees a Q2 report roughly matching our expectations.
Small Q2 beat amid solid underlying performance In strong position to act on opportunities Fair valu...
Luxbright AB (”Luxbright” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det första halv...
Redeye provides its comment on Mendus’ Q2 2024 report.
I en utmanande omgivning tar New Wave marknadsandelar och ökar nu marknadssatsningarna.
Redeye regards BrightBid’s Q2 as a mixed-bag quarter, where the substantial cost cuts are the positi...
CoinShares International (CS) posted a strong adjusted EBITDA in Q224 of £26.
Solteq is set to start showing clearly improved profitability figures, with the toughest actions now...
Redeye returns with an updated view of Egetis Therapeutics following the Q2 report and recent events...
Redeye comments on Heliospectra’s Q2 results, noting that sales were weaker than expected due to sho...
